UNDERSTANDING FUNCTIONAL TARGETING TREATMENTS (DEPRESSION, COGNITIVE IMPAIRMENT, SMOKING ADDICTION) THROUGH DEEP TRANSCRANIAL MAGNETIC STIMULATION (dTMS), NEUROMODULATION REVOLUTION

from youarewithinthenorms.com

NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

Deep TMS: From Electric Frogs to Brain Health

🧠 🧠 🧠

This source examines the historical evolution and contemporary applications of Deep Transcranial Magnetic Stimulation (dTMS), a non-invasive brain stimulation technique. It traces the evolution of neurostimulation from early electrical experiments to the targeted magnetic fields used today, highlighting how DTMS offers a paradigm shift in mental health treatment by stimulating specific brain regions without surgery or medication.

The discussion emphasizes the safety and efficacy of DTMS for conditions like depression, OCD, and smoking addiction, detailing its unique “H-coil” technology that allows for deeper and broader brain penetration compared to earlier TMS devices.

Ultimately, the text presents DTMS as a revolutionary advancement in psychiatric care, offering hope and new treatment options with less stigma and more targeted precision.

90867

90869

🧠🧠🧠

DONATE LEGAL DEFENSE

OR SEND

TO CASH APP:$docnorm

ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE

BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!

FOR NOW, YOU ARE WITHIN

REFERENCES:

Detailed Briefing: Deep TMS Transformation

I. Executive Summary

This briefing summarizes key information regarding Deep Transcranial Magnetic Stimulation (DTMS), tracing its historical roots, explaining its mechanisms and unique advantages, detailing its current applications and effectiveness, and outlining future directions. DTMS represents a significant advancement in neuromodulation, offering a non-invasive, safe, and effective treatment for a range of neuropsychiatric disorders, particularly for those resistant to traditional therapies. It signifies a “paradigm shift” in mental health treatment by enabling targeted brain activity modulation without surgery or systemic medication side effects.

II. Historical Context and Evolution of Neuromodulation

The journey to DTMS began with early explorations into electricity and medicine, highlighting a continuous evolution in understanding and manipulating brain activity:

• 18th Century Foundations: Early experiments by Volta and Galvani with electricity on living tissue laid the groundwork. Aldini even “tried his voltaic pile on himself,” demonstrating early, albeit crude, attempts at human application.
• 20th Century: Electroconvulsive Therapy (ECT): ECT emerged as an effective tool for severe mental illness. However, it “always carried a lot of stigma” due to its whole-brain seizure induction, anesthesia, and side effects like memory loss, as dramatized in popular culture (“movies like One Flew Over the Cuckoo’s Nest didn’t help”).
• 1985: Birth of TMS: A critical turning point was Anthony Barker’s development of the first TMS device in 1985. This marked the realization that “you could target specific brain regions” non-invasively using magnetic fields.
• Shift to Functional Targeting: The “real breakthrough for psychiatry” was the move from global to functional brain stimulation. Imaging studies identified the left dorsolateral prefrontal cortex (DLPFC) as a key target for depression, making TMS a “real contender in mental health treatment.” This represented the “first time we could modulate brain activity without surgery or medication and with much less stigma than ECT.”

III. Deep TMS (DTMS): Technical Innovations and Mechanism

DTMS distinguishes itself from earlier TMS technology through significant technical advancements, primarily the H-coil:

• The H-Coil: Developed by Brainsway, the H-coil is the “big technical leap” that differentiates DTMS. Unlike traditional figure-8 coils that reach only about 0.7 cm below the skull, the H-coil can penetrate “much deeper up to 3 cm,” allowing stimulation of “broader and deeper brain regions.” This depth is crucial for conditions like depression, OCD, and smoking addiction.
• Mechanism of Action: DTMS works by generating a “pulsed magnetic field which passes through the scalp and skull without resistance.” This field “induces an electric current in the targeted brain area, causing neurons to depolarize.” Repeated sessions promote neuroplasticity, helping the “brain rewire itself and normalize dysfunctional networks.” This process is likened to “physical therapy for the brain, but with magnets.”

IV. Safety Profile and Patient Experience

DTMS is characterized by a strong safety record and general tolerability, addressing common patient concerns:

• Safety Data: “The data are really reassuring.” The most common side effect is a “mild headache,” typically during the first few sessions, easily managed with over-the-counter pain relievers.
• Low Seizure Risk: The risk of seizure is “extremely low, less than one in 10,000 sessions.”
• No Anesthesia or Systemic Side Effects: Unlike ECT, DTMS involves “no anesthesia, no memory loss, and no systemic side effects.”
• Non-Invasive and Well-Tolerated: Providers frequently “debunking myths about TMS,” emphasizing its non-invasive nature, safety, and comfort provided by the helmet design of the H-coil. It’s “really just a series of magnetic pulses.”

V. Approved Indications and Efficacy

The FDA has cleared DTMS for several neuropsychiatric conditions, with expanding applications and impressive efficacy rates:

• Major Depressive Disorder (MDD): Cleared for MDD, including late-life depression and anxious depression.
• Protocols: A typical course involves 36 sessions (5 days/week for 4-6 weeks), sometimes with maintenance sessions.
• Accelerated Protocols: A significant advancement, these condense weeks of treatment into just 5 days with multiple daily sessions. Clinical trials have shown “remission rates as high as 79% with these accelerated approaches,” which is “honestly remarkable compared to traditional medication trials.”
• Late-Life Depression: DTMS is the “first and only TMS device cleared for patients up to age 86,” addressing a population often excluded from trials.
• Obsessive-Compulsive Disorder (OCD): The H7 coil targets the medial prefrontal cortex and anterior cingulate. The protocol includes “symptom provocation before each session.”
• Efficacy: “Over a third of OCD patients respond.”
• Smoking Addiction: The H4 coil targets the insula and prefrontal cortex, with a “brief craving provocation before each session.”
• Efficacy: “About 28% of highly addicted smokers achieve 4 weeks of abstinence, which is better than most medications or behavioral therapies alone.”
• Patient Stories: Beyond statistics, the “patient stories” are powerful, illustrating profound transformations:
• A 45-year-old teacher with treatment-resistant depression, after accelerated DTMS, said: “I feel alive again. It was like watching someone come back to life.”
• An elderly patient, depressed for years, “was smiling, reconnecting with family, just living again” after DTMS.
• “Patients who were stuck in endless rituals finally get relief” from OCD.

VI. Practical Aspects and Implementation

Implementing DTMS involves thorough evaluation, clear protocols, and consideration of logistical factors:

• Pre-Treatment Evaluation: A “thorough evaluation” (medical, psychiatric, and screening for implants/contraindications) is essential, prioritizing safety. This includes checking for seizure history, metal in the head/neck, and certain medications.
• Session Details: Sessions typically last “about 20 minutes.” Patients are monitored, and progress is tracked using symptom rating scales (e.g., PHQ9 for depression, YBOCS for OCD). Informed consent is mandatory.
• Insurance Coverage: “Most commercial insurers and Medicare cover DTMS for depression,” with growing coverage for OCD and smoking cessation, though prior authorization may be required, and maintenance sessions are not always covered. Specific billing codes are used (90867, 90868, 90869).
• Clinic Setup: Establishing a TMS clinic requires “space, trained staff, and the right equipment.” Protocols for rare emergencies (like seizures) are crucial.

VII. Future Directions and the Neuromodulation Revolution

The field of neuromodulation, particularly DTMS, is rapidly advancing, promising even more personalized and effective treatments:

• Precision Psychiatry: Moving beyond scalp-based targeting (e.g., 5 cm rule, Beam F3 method) to MRI-based and fMRI-guided targeting will “personalize treatment based on each person’s brain connectivity.” This is “a big step toward precision psychiatry.”
• Accelerated Protocols: “Game-changer” protocols like Stanford’s accelerated theta-burst protocol for depression are compressing “weeks of therapy into just five days,” leading to rapid and high remission rates.
• Network-Based Targeting: For OCD and other conditions, there is promising research into stimulating “specific circuits involved in compulsive behaviors.”
• Integration of AI and Machine Learning: Future advancements will likely involve “integrating artificial intelligence and machine learning, using individual brain imaging data to personalize targeting and dosing for each patient.”
• Expanding Indications: Ongoing clinical trials are exploring DTMS for PTSD, schizophrenia, cognitive impairment, and more, aiming to offer “rapid effective treatment for a much wider range of neuropsychiatric disorders.”
• Neuromodulation Revolution: The speakers believe “we’re in the middle of a neuromodulation revolution,” asserting it is “becoming a core part of psychiatric care alongside medication and therapy.”
• Advocacy and Hope: Despite barriers like access, stigma, and insurance hurdles, continued advocacy is vital to integrate these treatments into mainstream care, reduce stigma, and provide “hope, resilience and giving people options when they feel out of them.” The pace of innovation is “incredible,” and we are “just scratching the surface of what’s possible.”